Pangaea Oncology Statistics
Total Valuation
Pangaea Oncology has a market cap or net worth of EUR 53.66 million. The enterprise value is 55.24 million.
Market Cap | 53.66M |
Enterprise Value | 55.24M |
Important Dates
The next estimated earnings date is Tuesday, October 29, 2024.
Earnings Date | Oct 29, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Pangaea Oncology has 30.14 million shares outstanding. The number of shares has decreased by -0.43% in one year.
Shares Outstanding | 30.14M |
Shares Change (YoY) | -0.43% |
Shares Change (QoQ) | -0.42% |
Owned by Insiders (%) | n/a |
Owned by Institutions (%) | n/a |
Float | 7.92M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 5.39 |
PB Ratio | 3.01 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -11.86 |
EV / Sales | 5.55 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | -20.82 |
Financial Position
The company has a current ratio of 1.34, with a Debt / Equity ratio of 17.99.
Current Ratio | 1.34 |
Quick Ratio | 1.27 |
Debt / Equity | 17.99 |
Debt / EBITDA | n/a |
Debt / FCF | -1.28 |
Interest Coverage | -25.71 |
Financial Efficiency
Return on equity (ROE) is -22.89% and return on invested capital (ROIC) is -9.02%.
Return on Equity (ROE) | -22.89% |
Return on Assets (ROA) | -7.52% |
Return on Capital (ROIC) | -9.02% |
Revenue Per Employee | 66,811 |
Profits Per Employee | -31,251 |
Employee Count | 149 |
Asset Turnover | 0.35 |
Inventory Turnover | 5.05 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +212.93% in the last 52 weeks. The beta is 0.07, so Pangaea Oncology's price volatility has been lower than the market average.
Beta (5Y) | 0.07 |
52-Week Price Change | +212.93% |
50-Day Moving Average | 1.48 |
200-Day Moving Average | 1.47 |
Relative Strength Index (RSI) | 99.87 |
Average Volume (20 Days) | 1,082 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Pangaea Oncology had revenue of EUR 9.95 million and -4.66 million in losses. Loss per share was -0.15.
Revenue | 9.95M |
Gross Profit | 7.56M |
Operating Income | -3.44M |
Pretax Income | -3.51M |
Net Income | -4.66M |
EBITDA | -2.69M |
EBIT | -3.44M |
Loss Per Share | -0.15 |
Balance Sheet
The company has 2.79 million in cash and 3.38 million in debt, giving a net cash position of -593,314 or -0.02 per share.
Cash & Cash Equivalents | 2.79M |
Total Debt | 3.38M |
Net Cash | -593,314 |
Net Cash Per Share | -0.02 |
Equity (Book Value) | 18.81M |
Book Value Per Share | 0.59 |
Working Capital | 2.46M |
Cash Flow
In the last 12 months, operating cash flow was -2.40 million and capital expenditures -256,021, giving a free cash flow of -2.65 million.
Operating Cash Flow | -2.40M |
Capital Expenditures | -256,021 |
Free Cash Flow | -2.65M |
FCF Per Share | -0.09 |
Margins
Gross margin is 75.92%, with operating and profit margins of -34.59% and -46.78%.
Gross Margin | 75.92% |
Operating Margin | -34.59% |
Pretax Margin | -35.22% |
Profit Margin | -46.78% |
EBITDA Margin | -27.07% |
EBIT Margin | -34.59% |
FCF Margin | -26.66% |
Dividends & Yields
Pangaea Oncology does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | 0.43% |
Shareholder Yield | 0.43% |
Earnings Yield | -8.68% |
FCF Yield | -4.95% |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |